132 related articles for article (PubMed ID: 21599581)
21. Molecular targets for cancer therapy in the PI3K/AKT/mTOR pathway.
Polivka J; Janku F
Pharmacol Ther; 2014 May; 142(2):164-75. PubMed ID: 24333502
[TBL] [Abstract][Full Text] [Related]
22. [mTOR inhibitor].
Muro K
Gan To Kagaku Ryoho; 2011 Jan; 38(1):7-11. PubMed ID: 21368454
[TBL] [Abstract][Full Text] [Related]
23. Role of the phosphatidylinositol 3-kinase/Akt and mTOR/P70S6-kinase pathways in the proliferation and apoptosis in multiple myeloma.
Pene F; Claessens YE; Muller O; Viguié F; Mayeux P; Dreyfus F; Lacombe C; Bouscary D
Oncogene; 2002 Sep; 21(43):6587-97. PubMed ID: 12242656
[TBL] [Abstract][Full Text] [Related]
24. [mTOR complexes -- molecular spiders in molecular networks].
Kopper L; Tímár J
Magy Onkol; 2011 Nov; 55(4):287-94. PubMed ID: 22128312
[TBL] [Abstract][Full Text] [Related]
25. New strategies to overcome resistance to mammalian target of rapamycin inhibitors in breast cancer.
Vicier C; Dieci MV; Andre F
Curr Opin Oncol; 2013 Nov; 25(6):587-93. PubMed ID: 24097108
[TBL] [Abstract][Full Text] [Related]
26. Knockdown of DEPTOR inhibits cell proliferation and increases chemosensitivity to melphalan in human multiple myeloma RPMI-8226 cells via inhibiting PI3K/AKT activity.
Zhang HR; Chen JM; Zeng ZY; Que WZ
J Int Med Res; 2013 Jun; 41(3):584-95. PubMed ID: 23613505
[TBL] [Abstract][Full Text] [Related]
27. Mammalian target of rapamycin (mTOR) as a potential therapeutic target in various diseases.
Kaur A; Sharma S
Inflammopharmacology; 2017 Jun; 25(3):293-312. PubMed ID: 28417246
[TBL] [Abstract][Full Text] [Related]
28. Distinct signaling mechanisms of mTORC1 and mTORC2 in glioblastoma multiforme: a tale of two complexes.
Jhanwar-Uniyal M; Gillick JL; Neil J; Tobias M; Thwing ZE; Murali R
Adv Biol Regul; 2015 Jan; 57():64-74. PubMed ID: 25442674
[TBL] [Abstract][Full Text] [Related]
29. Chemical probing of HER2-amplified cancer cells identifies TORC2 as a particularly effective secondary target for combination with lapatinib.
Amin DN; Ruiz-Saenz A; Gulizia N; Moasser MM
Oncotarget; 2015 Dec; 6(38):41123-33. PubMed ID: 26516700
[TBL] [Abstract][Full Text] [Related]
30. DEPTOR expression and response to thalidomide: toward a new therapeutic target in multiple myeloma?
de la Rubia J; Such E
Leuk Lymphoma; 2010 Nov; 51(11):1960-1. PubMed ID: 21077744
[No Abstract] [Full Text] [Related]
31. RES-529: a PI3K/AKT/mTOR pathway inhibitor that dissociates the mTORC1 and mTORC2 complexes.
Weinberg MA
Anticancer Drugs; 2016 Jul; 27(6):475-87. PubMed ID: 26918392
[TBL] [Abstract][Full Text] [Related]
32. SC06, a novel small molecule compound, displays preclinical activity against multiple myeloma by disrupting the mTOR signaling pathway.
Han K; Xu X; Xu Z; Chen G; Zeng Y; Zhang Z; Cao B; Kong Y; Tang X; Mao X
Sci Rep; 2015 Sep; 5():12809. PubMed ID: 26329846
[TBL] [Abstract][Full Text] [Related]
33. Mammalian target of rapamycin pathway activity in alveolar soft part sarcoma.
Reis H; Hager T; Wohlschlaeger J; Bauer S; Katenkamp K; Katenkamp D; Baba HA
Hum Pathol; 2013 Oct; 44(10):2266-74. PubMed ID: 23871289
[TBL] [Abstract][Full Text] [Related]
34. Next generation of mammalian target of rapamycin inhibitors for the treatment of cancer.
Nelson V; Altman JK; Platanias LC
Expert Opin Investig Drugs; 2013 Jun; 22(6):715-22. PubMed ID: 23544840
[TBL] [Abstract][Full Text] [Related]
35. Beyond rapalog therapy: preclinical pharmacology and antitumor activity of WYE-125132, an ATP-competitive and specific inhibitor of mTORC1 and mTORC2.
Yu K; Shi C; Toral-Barza L; Lucas J; Shor B; Kim JE; Zhang WG; Mahoney R; Gaydos C; Tardio L; Kim SK; Conant R; Curran K; Kaplan J; Verheijen J; Ayral-Kaloustian S; Mansour TS; Abraham RT; Zask A; Gibbons JJ
Cancer Res; 2010 Jan; 70(2):621-31. PubMed ID: 20068177
[TBL] [Abstract][Full Text] [Related]
36. Immunohistochemical Expression of mTOR in Multiple Myeloma: Retrospective Analysis of 31 Cases, a Clinicopathological Study.
Stockwin W; Johnson P; Vajpayee N
Ann Clin Lab Sci; 2016; 46(2):125-31. PubMed ID: 27098617
[TBL] [Abstract][Full Text] [Related]
37. mTOR in renal cell cancer: modulator of tumor biology and therapeutic target.
Wysocki PJ
Expert Rev Mol Diagn; 2009 Apr; 9(3):231-41. PubMed ID: 19379082
[TBL] [Abstract][Full Text] [Related]
38. Targeting the mTOR pathway in breast cancer.
Liu J; Li HQ; Zhou FX; Yu JW; Sun L; Han ZH
Tumour Biol; 2017 Jun; 39(6):1010428317710825. PubMed ID: 28639903
[TBL] [Abstract][Full Text] [Related]
39. Evolutionarily conserved regulation of TOR signalling.
Takahara T; Maeda T
J Biochem; 2013 Jul; 154(1):1-10. PubMed ID: 23698095
[TBL] [Abstract][Full Text] [Related]
40. Targeting the phosphatidylinositol 3-kinase (PI3K)/AKT/mammalian target of rapamycin (mTOR) pathway: an emerging treatment strategy for squamous cell lung carcinoma.
Beck JT; Ismail A; Tolomeo C
Cancer Treat Rev; 2014 Sep; 40(8):980-9. PubMed ID: 25037117
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
